VMD-928 is under clinical development by VM Discovery and currently in Phase I for Colon Cancer. According to GlobalData, Phase I drugs for Colon Cancer have a 56% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how VMD-928’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

VMD-928 overview

VMD-928 is under development for the treatment of lymphoma, thymic carcinoma, thymoma, pancreatic cancer and mesothelioma, head and neck squamous cell carcinoma, ovarian cancer, hepatocellular carcinoma, squamous cell carcinoma of lung (squamous NSCLC), esophageal cancer, adenoid cystic carcinoma, prostate cancer, cervical cancer, gastric cancer, melanoma, acute myeloid leukemia, pancreatic carcinoma. It is formulated as a capsule and administered through oral route. The drug candidate acts by targeting tropomyosin receptor kinase A (TrkA). It was under development for non-Hodgkins' lymphoma.

For a complete picture of VMD-928’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.